# Study to Evaluate the Pharmacokinetic (PK) Interactions Between GSK3640254 and Dolutegravir (DTG)

> **NCT03816696** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 16 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** GSK3640254
- **DRUG:** DTG

## Key facts

- **NCT ID:** NCT03816696
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-23
- **Primary completion:** 2019-03-30
- **Final completion:** 2019-04-10
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2020-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03816696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03816696, "Study to Evaluate the Pharmacokinetic (PK) Interactions Between GSK3640254 and Dolutegravir (DTG)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03816696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*